語系:
繁體中文
English
日文
簡体中文
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Formulating poorly water soluble dru...
~
Miller, Dave A.
Formulating poorly water soluble drugs[electronic resource] /
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
杜威分類號:
615.19
書名/作者:
Formulating poorly water soluble drugs/ edited by Robert O. Williams III, Alan B. Watts, Dave A. Miller.
其他作者:
Williams, Robert O.
出版者:
Cham : : Springer International Publishing :, 2016.
面頁冊數:
xiv, 779 p. : : ill., digital ;; 24 cm.
Contained By:
Springer eBooks
標題:
Drug development.
標題:
Drugs - Design.
標題:
Biomedicine.
標題:
Pharmaceutical Sciences/Technology.
ISBN:
9783319426099
ISBN:
9783319426075
內容註:
Route-Specific Challenges in Delivery of Poorly Water Soluble Drugs -- Optimizing the Formulation of Poorly Water Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle Size Reduction Techniques -- Solubilized Formulations -- Injectable Formulations of Poorly Water Soluble Drugs -- Design and Development of Self-Emulsifying Lipid Formulations for Improving Oral Bioavailability of Poorly Water-Soluble and Lipophilic Drugs -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water Soluble Drugs -- Regulatory Considerations for Development and Commercialization of Poorly Water Soluble Drugs.
摘要、提要註:
The objective of this volume is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist's approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound's physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at minimum a working knowledge of each of the abovementioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop.
電子資源:
http://dx.doi.org/10.1007/978-3-319-42609-9
Formulating poorly water soluble drugs[electronic resource] /
Formulating poorly water soluble drugs
[electronic resource] /edited by Robert O. Williams III, Alan B. Watts, Dave A. Miller. - 2nd ed. - Cham :Springer International Publishing :2016. - xiv, 779 p. :ill., digital ;24 cm. - AAPS advances in the pharmaceutical sciences series,v.222210-7371 ;. - AAPS advances in the pharmaceutical sciences series ;3..
Route-Specific Challenges in Delivery of Poorly Water Soluble Drugs -- Optimizing the Formulation of Poorly Water Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle Size Reduction Techniques -- Solubilized Formulations -- Injectable Formulations of Poorly Water Soluble Drugs -- Design and Development of Self-Emulsifying Lipid Formulations for Improving Oral Bioavailability of Poorly Water-Soluble and Lipophilic Drugs -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water Soluble Drugs -- Regulatory Considerations for Development and Commercialization of Poorly Water Soluble Drugs.
The objective of this volume is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist's approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound's physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at minimum a working knowledge of each of the abovementioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop.
ISBN: 9783319426099
Standard No.: 10.1007/978-3-319-42609-9doiSubjects--Topical Terms:
339189
Drug development.
LC Class. No.: RM301.25 / .F67 2016
Dewey Class. No.: 615.19
Formulating poorly water soluble drugs[electronic resource] /
LDR
:03127nam a2200337 a 4500
001
476889
003
DE-He213
005
20161216102322.0
006
m d
007
cr nn 008maaau
008
181208s2016 gw s 0 eng d
020
$a
9783319426099
$q
(electronic bk.)
020
$a
9783319426075
$q
(paper)
024
7
$a
10.1007/978-3-319-42609-9
$2
doi
035
$a
978-3-319-42609-9
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RM301.25
$b
.F67 2016
072
7
$a
TDCW
$2
bicssc
072
7
$a
MED072000
$2
bisacsh
082
0 4
$a
615.19
$2
23
090
$a
RM301.25
$b
.F726 2016
245
0 0
$a
Formulating poorly water soluble drugs
$h
[electronic resource] /
$c
edited by Robert O. Williams III, Alan B. Watts, Dave A. Miller.
250
$a
2nd ed.
260
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Springer,
$c
2016.
300
$a
xiv, 779 p. :
$b
ill., digital ;
$c
24 cm.
490
1
$a
AAPS advances in the pharmaceutical sciences series,
$x
2210-7371 ;
$v
v.22
505
0
$a
Route-Specific Challenges in Delivery of Poorly Water Soluble Drugs -- Optimizing the Formulation of Poorly Water Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle Size Reduction Techniques -- Solubilized Formulations -- Injectable Formulations of Poorly Water Soluble Drugs -- Design and Development of Self-Emulsifying Lipid Formulations for Improving Oral Bioavailability of Poorly Water-Soluble and Lipophilic Drugs -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water Soluble Drugs -- Regulatory Considerations for Development and Commercialization of Poorly Water Soluble Drugs.
520
$a
The objective of this volume is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist's approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound's physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at minimum a working knowledge of each of the abovementioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop.
650
0
$a
Drug development.
$3
339189
650
0
$a
Drugs
$x
Design.
$3
424032
650
1 4
$a
Biomedicine.
$3
463454
650
2 4
$a
Pharmaceutical Sciences/Technology.
$3
464319
700
1
$a
Williams, Robert O.
$3
466097
700
1
$a
Watts, Alan B.
$3
466098
700
1
$a
Miller, Dave A.
$3
466099
710
2
$a
SpringerLink (Online service)
$3
463450
773
0
$t
Springer eBooks
830
0
$a
AAPS advances in the pharmaceutical sciences series ;
$v
3.
$3
466100
856
4 0
$u
http://dx.doi.org/10.1007/978-3-319-42609-9
950
$a
Biomedical and Life Sciences (Springer-11642)
筆 0 讀者評論
多媒體
多媒體檔案
http://dx.doi.org/10.1007/978-3-319-42609-9
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼
登入